Breast CancerPhase 3TAILOR RTNCT03488693
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
A Phase 3 study testing Radiation and No Radiation in people with Breast Cancer, run by Canadian Cancer Trials Group at 485 sites in 2 countries.
Trial summary
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back. Read more about this study
- Who is it for?
- Ages 35 years and older, women only
- Conditions the study is for
- Breast Cancer
- What is being tested?
- Radiation and No Radiation
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 2,138 participants
- Where
- 485 sitesin 2 countries
- Study dates
- 16 Oct 2018to 30 Dec 2027
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 35 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients must be women with newly diagnosed histologically proven invasive carcinoma of the breast with no evidence of metastases, staged as per site standard of care.
- Patients must have been treated by BCS or mastectomy with clear margins of excision. Post-mastectomy positive margins for invasive disease and/or DCIS is not allowed. Multifocal disease (i.e. the presence of two or more foci or breast cancer within the same breast quadrant) and multicentric disease (i.e. the presence of two or more foci of breast cancer in different quadrants of the same breast) are allowed.
- Patients with T3N0 disease are eligible.
- Patients with disease limited to nodal micrometastases are eligible
- Patients with nodal macrometastases (>2mm) treated by axillary dissection must have 1-3 positive axillary nodes (macrometastases, > 2 mm).
- Patients treated by mastectomy and SLNB alone must have only 1-2 positive axillary nodes (macrometastases, > 2 mm).
Show all 20Show fewer
- Patients must be ER ≥ 1% and HER2 negative on local testing
- Patients must have an Oncotype DX recurrence score ≤25 obtained from testing of breast tumour tissue from a core biopsy or from the surgical specimen.
- Patient must consent to provision of, and investigator(s) must agree to submit to the CCTG Central Tumour Bank, a representative formalin fixed paraffin block of tumour tissue in order that the specific correlative marker assays described in the protocol may be conducted
- Patient must consent to provision of samples of blood in order that the specific correlative marker assays described in the protocol may be conducted.
- Patients must have had endocrine therapy initiated or planned for ≥ 5 years. Premenopausal women will receive ovarian ablation plus aromatase inhibitor therapy or tamoxifen if adjuvant chemotherapy was not administered. For all patients, endocrine therapy can be given concurrently or following RT.
- Patients may or may not have had adjuvant chemotherapy.
- RT must commence within 16 weeks of definitive surgery if the patient is not treated with chemotherapy. If adjuvant chemotherapy is given, RT must begin within 12 weeks after the last dose. (Note: adjuvant chemotherapy may be ongoing at the time of randomization). Definitive surgery is defined as the last breast cancer-related surgery.
- Patient's ECOG performance status must be 0, 1 or 2.
- Patient's age must be ≥ 35 years.
- For the first 736 eligible English or French-speaking subjects who have agreed to optional questionnaire completion: Patient is able (i.e. sufficiently fluent) and willing to complete the quality of life, health utilities and lost productivity questionnaires in either English or French (note: enrollment completed 2022Aug02)
- Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements
- Patients must be accessible for treatment and follow-up. Investigators must assure themselves the patients randomized on this trial will be available for complete documentation of the treatment, adverse events, and follow-up.
- In accordance with CCTG policy, protocol treatment is to begin within 6 weeks of patient randomization.
- Women of childbearing potential must have agreed to use an effective contraceptive method. A woman is considered to be of "childbearing potential" if she has had menses at any time in the preceding 12 consecutive months.
Who cannot join
- Patients with nodal disease limited to isolated tumour cells (pN0i+ < 0.2 mm).
- Patients with pT3N1 and pT4 disease (Note: patients with T3N0 are eligible).
- Any prior history, not including the index cancer, of ipsilateral invasive breast cancer or ipsilateral DCIS treated with radiation therapy. (Patients with synchronous or previous ipsilateral LCIS are eligible.)
- Synchronous or previous contralateral invasive breast cancer. (Patients with contralateral DCIS are eligible unless previously treated with radiation.)
- History of non-breast malignancies except adequately treated non-melanoma skin cancers, in situ cancers treated by local excision or other cancers curatively treated with no evidence of disease for ≥ 5 years.
- Patients who are pregnant.
Show all 10Show fewer
- Patients that have had prior ipsilateral chestwall/thoracic radiation.
- Patients treated with chemo or endocrine therapy administered in the neoadjuvant setting for breast cancer. Endocrine therapy exposure 12 weeks or less prior to surgery is permitted.
- Patients with serious non-malignant disease (e.g. cardiovascular, scleroderma etc.) which would preclude RT.
- Patients with any serious active or co-morbid medical conditions, laboratory abnormality, psychiatric illness, active or uncontrolled infections, or serious illnesses or medical conditions that would prevent the patient from participating or to be managed according to the protocol (according to investigator's decision).
Trial locations and contacts
485 sites in 2 countries.
334 sites in 2 countries
United States300 sites
Cleveland Clinic Akron General
Akron, Ohio, 44307
University of New Mexico Cancer Center
Albuquerque, New Mexico, 87106
Lovelace Radiation Oncology
Albuquerque, New Mexico, 87109
New Mexico Oncology Hematology Consultants
Albuquerque, New Mexico, 87109
American Fork Hospital / Huntsman Intermountain Cancer Center
American Fork, Utah, 84003
Kaiser Permanente-Anaheim
Anaheim, California, 92806
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, 48109
Luminis Health Anne Arundel Medical Center
Annapolis, Maryland, 21401
Langlade Hospital and Cancer Center
Antigo, Wisconsin, 54409
ThedaCare Regional Cancer Center
Appleton, Wisconsin, 54911
Mission Hospital
Asheville, North Carolina, 28801
Hope Women's Cancer Centers-Asheville
Asheville, North Carolina, 28816
Mount Sinai Queens
Astoria, New York, 11102
Grady Health System
Atlanta, Georgia, 30303
Emory University Hospital Midtown
Atlanta, Georgia, 30308
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322
Emory Saint Joseph's Hospital
Atlanta, Georgia, 30342
MultiCare Auburn Medical Center
Auburn, Washington, 98001
UCHealth University of Colorado Hospital
Aurora, Colorado, 80045
IU Health West Hospital
Avon, Indiana, 46123
UH Seidman Cancer Center at UH Avon Health Center
Avon, Ohio, 44011
University of Maryland/Greenebaum Cancer Center
Baltimore, Maryland, 21201
Greater Baltimore Medical Center
Baltimore, Maryland, 21204
Saint Agnes Hospital
Baltimore, Maryland, 21229
MedStar Franklin Square Medical Center/Weinberg Cancer Institute
Baltimore, Maryland, 21237
MedStar Good Samaritan Hospital
Baltimore, Maryland, 21239
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287
Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, 07920
MaineHealth Coastal Cancer Treatment Center
Bath, Maine, 04530
McLaren Cancer Institute-Bay City
Bay City, Michigan, 48706
Houston Methodist San Jacinto Hospital
Baytown, Texas, 77521
UHHS-Chagrin Highlands Medical Center
Beachwood, Ohio, 44122
UM Upper Chesapeake Medical Center
Bel Air, Maryland, 21014
Kaiser Permanente-Bellflower
Bellflower, California, 90706
Sanford Joe Lueken Cancer Center
Bemidji, Minnesota, 56601
Saint Charles Health System
Bend, Oregon, 97701
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California, 94704
Central Vermont Medical Center/National Life Cancer Treatment
Berlin Corners, Vermont, 05602
Suburban Hospital
Bethesda, Maryland, 20814
Billings Clinic Cancer Center
Billings, Montana, 59101
Sanford Bismarck Medical Center
Bismarck, North Dakota, 58501
Saint Joseph's/Candler - Bluffton Campus
Bluffton, South Carolina, 29910
Boca Raton Regional Hospital
Boca Raton, Florida, 33486
Prisma Health Cancer Institute - Spartanburg
Boiling Springs, South Carolina, 29316
Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho, 83706
Tufts Medical Center
Boston, Massachusetts, 02111
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215
Rocky Mountain Cancer Centers-Boulder
Boulder, Colorado, 80304
Lafayette Family Cancer Center-EMMC
Brewer, Maine, 04412
New York-Presbyterian/Brooklyn Methodist Hospital
Brooklyn, New York, 11215
Maimonides Medical Center
Brooklyn, New York, 11219
NYU Langone Hospital - Brooklyn
Brooklyn, New York, 11220
Bryn Mawr Hospital
Bryn Mawr, Pennsylvania, 19010
Lahey Hospital and Medical Center
Burlington, Massachusetts, 01805
University of Vermont Medical Center
Burlington, Vermont, 05401
Saint James Community Hospital and Cancer Treatment Center
Butte, Montana, 59701
Sands Cancer Center
Canandaigua, New York, 14424
Cleveland Clinic Mercy Hospital
Canton, Ohio, 44708
Aultman Health Foundation
Canton, Ohio, 44710
Saint Francis Medical Center
Cape Girardeau, Missouri, 63703
Carlisle Regional Cancer Center
Carlisle, Pennsylvania, 17015
IU Health North Hospital
Carmel, Indiana, 46032
Duke Cancer Center Cary
Cary, North Carolina, 27518
Sandra L Maxwell Cancer Center
Cedar City, Utah, 84720
Saint Luke's Hospital
Cedar Rapids, Iowa, 52402
Christiana Care Health System-Concord Health Center
Chadds Ford, Pennsylvania, 19317
Chambersburg Hospital
Chambersburg, Pennsylvania, 17201
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599
Geauga Hospital
Chardon, Ohio, 44024
Medical University of South Carolina
Charleston, South Carolina, 29425
University of Virginia Cancer Center
Charlottesville, Virginia, 22908
Northwestern University
Chicago, Illinois, 60611
Rush MD Anderson Cancer Center
Chicago, Illinois, 60612
University of Illinois
Chicago, Illinois, 60612
Swedish Covenant Hospital
Chicago, Illinois, 60625
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, 60637
Advocate Illinois Masonic Medical Center
Chicago, Illinois, 60657
McLaren Cancer Institute-Clarkston
Clarkston, Michigan, 48346
Morton Plant Hospital
Clearwater, Florida, 33756
Case Western Reserve University
Cleveland, Ohio, 44106
MetroHealth Medical Center
Cleveland, Ohio, 44109
Mercy Cancer Center-West Lakes
Clive, Iowa, 50325
Kootenai Health - Coeur d'Alene
Coeur d'Alene, Idaho, 83814
Penrose-Saint Francis Healthcare
Colorado Springs, Colorado, 80907
UCHealth Memorial Hospital Central
Colorado Springs, Colorado, 80909
Memorial Hospital North
Colorado Springs, Colorado, 80920
Saint Francis Cancer Center
Colorado Springs, Colorado, 80923
MU Health - University Hospital/Ellis Fischel Cancer Center
Columbia, Missouri, 65212
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210
Riverside Methodist Hospital
Columbus, Ohio, 43214
Grant Medical Center
Columbus, Ohio, 43215
The Mark H Zangmeister Center
Columbus, Ohio, 43219
Memorial Sloan Kettering Commack
Commack, New York, 11725
New Hampshire Oncology Hematology PA-Concord
Concord, New Hampshire, 03301
MD Anderson in The Woodlands
Conroe, Texas, 77384
Mary Imogene Bassett Hospital
Cooperstown, New York, 13326
UM Sylvester Comprehensive Cancer Center at Coral Gables
Coral Gables, Florida, 33146
City of Hope Corona
Corona, California, 92882
Good Samaritan Hospital
Corvallis, Oregon, 97330
Greater Regional Medical Center
Creston, Iowa, 50801
UChicago Medicine Northwest Indiana
Crown Point, Indiana, 46307
Houston Methodist Cypress Hospital
Cypress, Texas, 77429
Parkland Memorial Hospital
Dallas, Texas, 75235
UT Southwestern/Simmons Cancer Center-Dallas
Dallas, Texas, 75390
Danbury Hospital
Danbury, Connecticut, 06810
Noyes Memorial Hospital/Myers Cancer Center
Dansville, New York, 14437
Corewell Health Dearborn Hospital
Dearborn, Michigan, 48124
Emory Decatur Hospital
Decatur, Georgia, 30033
Decatur Memorial Hospital
Decatur, Illinois, 62526
UM Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, Florida, 33442
Northwestern Medicine Cancer Center Kishwaukee
DeKalb, Illinois, 60115
Delaware Health Center-Grady Cancer Center
Delaware, Ohio, 43015
UCHealth - Cherry Creek
Denver, Colorado, 80206
AdventHealth Porter
Denver, Colorado, 80210
Iowa Methodist Medical Center
Des Moines, Iowa, 50309
Mercy Medical Center - Des Moines
Des Moines, Iowa, 50314
Wentworth-Douglass Hospital
Dover, New Hampshire, 03820
City of Hope Comprehensive Cancer Center
Duarte, California, 91010
Kaiser Permanente Dublin
Dublin, California, 94568
Dublin Methodist Hospital
Dublin, Ohio, 43016
Miller-Dwan Hospital
Duluth, Minnesota, 55805
Duke University Medical Center
Durham, North Carolina, 27710
University of Maryland Shore Medical Center at Easton
Easton, Maryland, 21601
HSHS Sacred Heart Hospital
Eau Claire, Wisconsin, 54701
Marshfield Medical Center-EC Cancer Center
Eau Claire, Wisconsin, 54701
Saint Elizabeth Healthcare Edgewood
Edgewood, Kentucky, 41017
Crossroads Cancer Center
Effingham, Illinois, 62401
Mercy Cancer Center-Elyria
Elyria, Ohio, 44035
UC San Diego Health System - Encinitas
Encinitas, California, 92024
Englewood Hospital and Medical Center
Englewood, New Jersey, 07631
Ephrata Cancer Center
Ephrata, Pennsylvania, 17522
UPMC Hillman Cancer Center Erie
Erie, Pennsylvania, 16505
Saint Vincent Hospital
Erie, Pennsylvania, 16544
NorthShore University HealthSystem-Evanston Hospital
Evanston, Illinois, 60201
Exeter Hospital
Exeter, New Hampshire, 03833
Fairbanks Memorial Hospital
Fairbanks, Alaska, 99701
Farmington Health Center
Farmington, Utah, 84025
Corewell Health Farmington Hills Hospital
Farmington Hills, Michigan, 48336
UPMC Cancer Center at UPMC Horizon
Farrell, Pennsylvania, 16121
IU Health Central Indiana Cancer Centers-Fishers
Fishers, Indiana, 46037
Augusta Health Center for Cancer and Blood Disorders
Fishersville, Virginia, 22939
McLaren Cancer Institute-Flint
Flint, Michigan, 48532
Poudre Valley Hospital
Fort Collins, Colorado, 80524
Broward Health Medical Center
Fort Lauderdale, Florida, 33316
Saint Elizabeth Healthcare Fort Thomas
Fort Thomas, Kentucky, 41075
CentraState Medical Center
Freehold, New Jersey, 07728
Fresno Cancer Center
Fresno, California, 93720
UF Health Cancer Institute - Gainesville
Gainesville, Florida, 32610
University of Texas Medical Branch
Galveston, Texas, 77555-0565
CaroMont Regional Medical Center
Gastonia, North Carolina, 28054
Northwestern Medicine Cancer Center Delnor
Geneva, Illinois, 60134
Adams Cancer Center
Gettysburg, Pennsylvania, 17325
MultiCare Gig Harbor Medical Park
Gig Harbor, Washington, 98335
Banner MD Anderson Cancer Center
Gilbert, Arizona, 85234
UM Baltimore Washington Medical Center/Tate Cancer Center
Glen Burnie, Maryland, 21061
NorthShore University HealthSystem-Glenbrook Hospital
Glenview, Illinois, 60026
Lutheran Hospital - Cancer Centers of Colorado
Golden, Colorado, 80401
Aurora Cancer Care-Grafton
Grafton, Wisconsin, 53024
Altru Cancer Center
Grand Forks, North Dakota, 58201
Corewell Health Grand Rapids Hospitals - Butterworth Hospital
Grand Rapids, Michigan, 49503
Trinity Health Grand Rapids Hospital
Grand Rapids, Michigan, 49503
Benefis Sletten Cancer Institute
Great Falls, Montana, 59405
Banner North Colorado Medical Center
Greeley, Colorado, 80631
UCHealth Greeley Hospital
Greeley, Colorado, 80631
Bellin Memorial Hospital
Green Bay, Wisconsin, 54301
Saint Vincent Hospital Cancer Center Green Bay
Green Bay, Wisconsin, 54301
Saint Vincent Hospital Cancer Center at Saint Mary's
Green Bay, Wisconsin, 54303
Aurora BayCare Medical Center
Green Bay, Wisconsin, 54311
UPMC Cancer Centers - Arnold Palmer Pavilion
Greensburg, Pennsylvania, 15601
Prisma Health Cancer Institute - Faris
Greenville, South Carolina, 29605
Saint Francis Cancer Center
Greenville, South Carolina, 29607
Prisma Health Cancer Institute - Eastside
Greenville, South Carolina, 29615
Self Regional Healthcare
Greenwood, South Carolina, 29646
Prisma Health Cancer Institute - Greer
Greer, South Carolina, 29650
Gibbs Cancer Center-Pelham
Greer, South Carolina, 29651
Mount Carmel Grove City Hospital
Grove City, Ohio, 43123
Smilow Cancer Hospital Care Center - Guilford
Guilford, Connecticut, 06437
Smilow Cancer Hospital-Hamden Care Center
Hamden, Connecticut, 06518
The Cancer Institute of New Jersey Hamilton
Hamilton, New Jersey, 08690
UPMC Pinnacle Cancer Center/Community Osteopathic Campus
Harrisburg, Pennsylvania, 17109
Memorial Sloan Kettering Westchester
Harrison, New York, 10604
Ingalls Memorial Hospital
Harvey, Illinois, 60426
Hi-Line Sletten Cancer Center
Havre, Montana, 59501
Margaret R Pardee Memorial Hospital
Hendersonville, North Carolina, 28791
Penn State Milton S Hershey Medical Center
Hershey, Pennsylvania, 17033-0850
NorthShore University HealthSystem-Highland Park Hospital
Highland Park, Illinois, 60035
UCHealth Highlands Ranch Hospital
Highlands Ranch, Colorado, 80129
The Radiation Oncology Center-Hilton Head/Bluffton
Hilton Head Island, South Carolina, 29926
Memorial Regional Hospital/Joe DiMaggio Children's Hospital
Hollywood, Florida, 33021
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
Houston, Texas, 77030
Ben Taub General Hospital
Houston, Texas, 77030
Houston Methodist Hospital
Houston, Texas, 77030
M D Anderson Cancer Center
Houston, Texas, 77030
Methodist Willowbrook Hospital
Houston, Texas, 77070
MD Anderson West Houston
Houston, Texas, 77079
Houston Methodist West Hospital
Houston, Texas, 77094
IRMC Cancer Center
Indiana, Pennsylvania, 15701
Indiana University/Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, 46202
IU Health Methodist Hospital
Indianapolis, Indiana, 46202
Community Cancer Center East
Indianapolis, Indiana, 46219
Community Cancer Center South
Indianapolis, Indiana, 46227
Community Cancer Center North
Indianapolis, Indiana, 46256
City of Hope at Irvine Lennar
Irvine, California, 92618
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980
MU Health Care Goldschmidt Cancer Center
Jefferson City, Missouri, 65109
Jefferson Hospital
Jefferson Hills, Pennsylvania, 15025
University of Wisconsin Carbone Cancer Center - Johnson Creek
Johnson Creek, Wisconsin, 53038
UPMC-Johnstown/John P. Murtha Regional Cancer Center
Johnstown, Pennsylvania, 15901
West Michigan Cancer Center
Kalamazoo, Michigan, 49007
University of Kansas Cancer Center
Kansas City, Kansas, 66160
University of Kansas Cancer Center - North
Kansas City, Missouri, 64154
Aurora Cancer Care-Kenosha South
Kenosha, Wisconsin, 53142
Gundersen Lutheran Medical Center
La Crosse, Wisconsin, 54601
UC San Diego Moores Cancer Center
La Jolla, California, 92093
Northwestern Medicine Lake Forest Hospital
Lake Forest, Illinois, 60045
City of Hope Antelope Valley
Lancaster, California, 93534
Lancaster General Ann B Barshinger Cancer Institute
Lancaster, Pennsylvania, 17601
Lancaster General Hospital
Lancaster, Pennsylvania, 17602
Karmanos Cancer Institute at McLaren Greater Lansing
Lansing, Michigan, 48910
Doctor's Hospital of Laredo
Laredo, Texas, 78041
UM Capital Region Medical Center
Largo, Maryland, 20774
Memorial Medical Center-Las Cruces
Las Cruces, New Mexico, 88011
Radiation Oncology Centers of Nevada Central
Las Vegas, Nevada, 89106
Radiation Oncology Centers of Nevada Southeast
Las Vegas, Nevada, 89119
MD Anderson League City
League City, Texas, 77573
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
Lebanon, New Hampshire, 03756
University of Kansas Cancer Center - Lee's Summit
Lee's Summit, Missouri, 64064
Saint Joseph Radiation Oncology Resource Center
Lexington, Kentucky, 40504
Saint Joseph Hospital East
Lexington, Kentucky, 40509
University of Kentucky/Markey Cancer Center
Lexington, Kentucky, 40536
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205
AdventHealth Littleton
Littleton, Colorado, 80122
Logan Regional Hospital
Logan, Utah, 84321
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California, 90027
Los Angeles General Medical Center
Los Angeles, California, 90033
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033
The James Graham Brown Cancer Center at University of Louisville
Louisville, Kentucky, 40202
UofL Health Medical Center Northeast
Louisville, Kentucky, 40245
Banner North Colorado Medical Center - Loveland Campus
Loveland, Colorado, 80539
Lowell General Hospital
Lowell, Massachusetts, 01854
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
Madison, Wisconsin, 53718
University of Wisconsin Carbone Cancer Center - University Hospital
Madison, Wisconsin, 53792
Solinsky Center for Cancer Care
Manchester, New Hampshire, 03103
OhioHealth Mansfield Hospital
Mansfield, Ohio, 44903
Aurora Bay Area Medical Group-Marinette
Marinette, Wisconsin, 54143
Marshfield Medical Center-Marshfield
Marshfield, Wisconsin, 54449
Loyola University Medical Center
Maywood, Illinois, 60153
UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion
Mechanicsburg, Pennsylvania, 17050
Riddle Memorial Hospital
Media, Pennsylvania, 19063
Baptist Memorial Hospital and Cancer Center-Memphis
Memphis, Tennessee, 38120
Froedtert Menomonee Falls Hospital
Menomonee Falls, Wisconsin, 53051
UH Seidman Cancer Center at Lake Health Mentor Campus
Mentor, Ohio, 44060
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida, 33136
Miami Cancer Institute
Miami, Florida, 33176
UH Seidman Cancer Center at Southwest General Hospital
Middleburg Heights, Ohio, 44130
Memorial Sloan Kettering Monmouth
Middletown, New Jersey, 07748
Bon Secours Saint Francis Medical Center
Midlothian, Virginia, 23114
Aurora Saint Luke's Medical Center
Milwaukee, Wisconsin, 53215
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226
Aurora Sinai Medical Center
Milwaukee, Wisconsin, 53233
NYU Langone Hospital - Long Island
Mineola, New York, 11501
Abbott-Northwestern Hospital
Minneapolis, Minnesota, 55407
Hennepin County Medical Center
Minneapolis, Minnesota, 55415
Marshfield Medical Center - Minocqua
Minocqua, Wisconsin, 54548
Community Medical Center
Missoula, Montana, 59804
Forbes Hospital
Monroeville, Pennsylvania, 15146
UPMC Cancer Center - Monroeville
Monroeville, Pennsylvania, 15146
Memorial Sloan Kettering Bergen
Montvale, New Jersey, 07645
West Virginia University Healthcare
Morgantown, West Virginia, 26506
McLaren Cancer Institute-Macomb
Mount Clemens, Michigan, 48043
McLaren Cancer Institute-Central Michigan
Mount Pleasant, Michigan, 48858
ProHealth D N Greenwald Center
Mukwonago, Wisconsin, 53149
IU Health Ball Memorial Hospital
Muncie, Indiana, 47303
Intermountain Medical Center
Murray, Utah, 84107
Trinity Health Muskegon Hospital
Muskegon, Michigan, 49444
Providence Queen of The Valley
Napa, California, 94558
Houston Methodist Saint John Hospital
Nassau Bay, Texas, 77058
Saint Peter's University Hospital
New Brunswick, New Jersey, 08901
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903
Yale University
New Haven, Connecticut, 06520
UC Comprehensive Cancer Center at Silver Cross
New Lenox, Illinois, 60451
Cancer Center of Western Wisconsin
New Richmond, Wisconsin, 54017
Mount Sinai Union Square
New York, New York, 10003
Mount Sinai Chelsea
New York, New York, 10011
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, New York, 10016
Mount Sinai West
New York, New York, 10019
Mount Sinai Hospital
New York, New York, 10029
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
New York, New York, 10032
Memorial Sloan Kettering Cancer Center
New York, New York, 10065
Helen F Graham Cancer Center
Newark, Delaware, 19713
Christiana Care Health System-Christiana Hospital
Newark, Delaware, 19718
Bryn Mawr Health Center
Newtown Square, Pennsylvania, 19073
Norwalk Hospital
Norwalk, Connecticut, 06856
Henry Ford Health Providence Novi Hospital
Novi, Michigan, 48374
Nyack Hospital
Nyack, New York, 10960
HSHS Saint Elizabeth's Hospital
O'Fallon, Illinois, 62269
Drexel Town Square Health Center
Oak Creek, Wisconsin, 53154
Kaiser Permanente Oakland-Broadway
Oakland, California, 94611
Mount Sinai South Nassau
Oceanside, New York, 11572
Canada34 sites
BCCA-Abbotsford Cancer Centre
Abbotsford British Columbia, British Columbia, V2S 1K2
Royal Victoria Regional Health Centre
Barrie, Ontario, L4M 6M2
Arthur J E Child Comprehensive Cancer Centre
Calgary, Alberta, T2N 5G2
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2
Health Sciences North
Greater Sudbury, Ontario, P3E 5J1
CSSS Champlain-Charles Le Moyne
Greenfield Park, Quebec, J4V 2H1
QEII Health Sciences Centre/Nova Scotia Health Authority
Halifax, Nova Scotia, B3H 2Y9
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, L8V 5C2
BCCA-Cancer Centre for the Southern Interior
Kelowna, British Columbia, V1Y 5L3
Kingston Health Sciences Centre
Kingston, Ontario, K7L 2V7
Waterloo Regional Health Network
Kitchener, Ontario, N2G 1G3
Hopital de la Cite-de-la-Sante
Laval, Quebec, H7M 3L9
London Regional Cancer Program
London, Ontario, N6A 4L6
Trillium Health Partners - Credit Valley Hospital
Mississauga, Ontario, L5M 2N1
CIUSSSEMTL-Hopital Maisonneuve-Rosemont
Montreal, Quebec, H1T 2M4
CHUM - Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec, H2X 3E4
The Research Institute of the McGill University Health Centre (MUHC)
Montreal, Quebec, H3H 2R9
Jewish General Hospital
Montreal, Quebec, H3T 1E2
Ottawa Hospital and Cancer Center-General Campus
Ottawa, Ontario, K1H 8L6
BCCA-Cancer Centre for the North
Prince George, British Columbia, V2M 7E9
CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ)
Québec, Quebec, G1R 2J6
Allan Blair Cancer Centre
Regina, Saskatchewan, S4T 7T1
Niagara Health System-Saint Catharines General
Saint Catharines, Ontario, L2S 0A9
Atlantic Health Sciences Corporation-Saint John Regional Hospital
Saint John, New Brunswick, E2L 4L2
Saskatoon Cancer Centre
Saskatoon, Saskatchewan, S7N 4H4
Algoma District Cancer Program Sault Area Hospital
Sault Ste. Marie, Ontario, P6B 0A8
Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
Sherbrooke, Quebec, J1H 5N4
Doctor H. Bliss Murphy Cancer Centre
St. John's, Newfoundland and Labrador, A1B 3V6
BCCA-Fraser Valley Cancer Centre
Surrey, British Columbia, V3V 1Z2
Odette Cancer Centre- Sunnybrook Health Sciences Centre
Toronto, Ontario, M4N 3M5
University Health Network-Princess Margaret Hospital
Toronto, Ontario, M5G 2M9
BCCA-Vancouver Cancer Centre
Vancouver, British Columbia, V5Z 4E6
BCCA-Vancouver Island Cancer Centre
Victoria, British Columbia, V8R 6V5
CancerCare Manitoba
Winnipeg, Manitoba, R3E 0V9
About this study
Official title: TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Read the detailed description
Women with node positive breast cancer normally will receive endocrine therapy and some may receive chemotherapy to help prevent the cancer from coming back. Many women will also receive radiotherapy to the whole breast/chest area and the surrounding lymph glands (called regional radiotherapy). No one really knows whether patients with low risk breast cancer need to receive regional radiotherapy. Some women may be getting regional radiotherapy who do not need it. These women may be exposed to the side effects of their treatment without benefit.
- Conditions
- Breast Cancer
- Being tested
- Radiation, No Radiation
- Medical subject headings
- Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RadiationRadiation
Radiotherapy given
No RadiationOther
No radiotherapy given
| Study group | Role | What they receive |
|---|---|---|
| No Regional Radiotherapy | Active comparator | A. Whole Breast Irradiation (WBI) following BCS or; B. No Radiotherapy (RT) following mastectomy Receives: Radiation: Radiation; Other: No Radiation |
| Regional Radiotherapy | Active comparator | A. WBI plus RT to the regional nodes (supraclavicular, non-dissected axillary, and internal mammary) following BCS or; B. RT to the chestwall and regional nodes (supraclavicular, non-dissected axillary, and internal mammary) following mastectomy Receives: Radiation: Radiation |
What is being measured
The primary outcome is the main question the study is designed to answer.
compare the breast cancer recurrence-free interval (BCRFI) between patients that received regional RT or not
Defined as time from randomization to time of invasive recurrent disease in the ipsilateral chestwall, breast, regional nodes, distant sites or death due to BC.
Measured: 9.5 years
Secondary outcomes (12)
Compare the invasive disease-free survival between patients that received regional RT or not.
Defined as time from randomization to time of invasive recurrent disease in the ipsilateral chestwall, breast, regional nodes, distant sites or death due to BC
Measured: 9.5 years
Compare the breast cancer mortality between patients that received regional RT or not.
Defined as death due to BC
Measured: 9.5 years
Compare the overall survival (OS) between patients that received regional RT or not
Defined as the time from randomization to the time of death from any cause
Measured: 9.5 years
Compare the locoregional recurrence-free interval (LRRFI) between patients that received regional RT or not.
Defined as time from randomization to time of invasive recurrent disease in the ipsilateral chestwall, breast or regional nodes, or death to due to BC
Measured: 9.5 years
Compare the distant recurrence-free interval (DRFI) between patients that received regional RT or not.
Defined as time from randomization to time of invasive recurrent disease in distant sites or death due to BC
Measured: 9.5 years
Number and severity of adverse events using the current CTCAE version 4
Measured: 9.5 years
Compare arm volume and mobility measurements between patients that received regional RT or not
A Fisher's Exact Test will be used to compare lymphedema and arm abduction deficit between two arms. Defined as a difference in arm abduction of 10% or greater in the comparison of the ipsilateral to the contralateral arm.
Measured: 9.5 years
Compare patient-reported outcomes (PROs) and the quality of life (QOL) between patients that received regional RT or not
using the NSABP Questionnaire for patients treated by BCS or mastectomy.
Measured: 9.5 years
Compare the quality of life (QOL) between patients that received regional RT or not
Overall QOL (EORTC QLQ-C30) will be compared between the two treatment groups using a similar approach.
Measured: 9.5 years
Compare the cost-effectiveness between patients that received regional RT or not
Costs will be expressed in $US and $CAN base currencies based on the final year of the study. An average cost per study subject by treatment arm for an overall mean cost per study arm will be generated
Measured: 9.5 years
Compare the quality of life (QOL) between patients that received regional RT or not
breast symptoms (NSABP B32 Questionnaire) will be compared between the two treatment groups using a similar approach.
Measured: 9.5 years
Compare the quality of life (QOL) between patients that received regional RT or not
skin symptoms and fatigue (EORTC QLQ-BR23) will be compared between the two treatment groups using a similar approach.
Measured: 9.5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Apr 2018
- Study start16 Oct 2018
- Primary completion1 Sep 2027 (estimated)
- Study completion30 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- More trials run by Canadian Cancer Trials GroupThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 2,138 participants (actual)
Sponsor and investigators
- Lead sponsor
- Canadian Cancer Trials Group
- Sponsor type
- Research network
- Collaborators
- Alliance for Clinical Trials in Oncology, Eastern Cooperative Oncology Group, NRG Oncology, SWOG Cancer Research Network
- Responsible party
- Sponsor
- Investigators
- Timothy Whelan, Study chair, Juravinski Cancer Centre at Hamilton Health Sciences, Ontario Canada
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03488693
- Sponsor's protocol ID
- CCTG MA.39
- Other IDs
- NCI-2017-02047
- Acronym
- TAILOR RT
- Status last verified
- Jun 2026
- First submitted
- 28 Mar 2018
- Last updated
- 1 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
- ClinicalTrials.gov ID
- NCT03488693
- Acronym / sponsor ID
- TAILOR RT / CCTG MA.39
- Conditions
- Breast Cancer
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 2,138 participants (actual)
- Lead sponsor
- Canadian Cancer Trials GroupResearch network
- Collaborators
- Alliance for Clinical Trials in Oncology, Eastern Cooperative Oncology Group, NRG Oncology, SWOG Cancer Research Network
- Study start
- 16 Oct 2018 (actual)
- Primary completion
- 1 Sep 2027 (estimated)
- Study completion
- 30 Dec 2027 (estimated)
- First posted
- 5 Apr 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Detailed description
Women with node positive breast cancer normally will receive endocrine therapy and some may receive chemotherapy to help prevent the cancer from coming back. Many women will also receive radiotherapy to the whole breast/chest area and the surrounding lymph glands (called regional radiotherapy). No one really knows whether patients with low risk breast cancer need to receive regional radiotherapy. Some women may be getting regional radiotherapy who do not need it. These women may be exposed to the side effects of their treatment without benefit.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| No Regional Radiotherapy | Active comparator | Radiation: Radiation, Other: No RadiationA. Whole Breast Irradiation (WBI) following BCS or; B. No Radiotherapy (RT) following mastectomy |
| Regional Radiotherapy | Active comparator | Radiation: RadiationA. WBI plus RT to the regional nodes (supraclavicular, non-dissected axillary, and internal mammary) following BCS or; B. RT to the chestwall and regional nodes (supraclavicular, non-dissected axillary, and internal mammary) following mastectomy |
Who may qualify
- Ages
- 35 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (20 listed)
- Patients must be women with newly diagnosed histologically proven invasive carcinoma of the breast with no evidence of metastases, staged as per site standard of care.
- Patients must have been treated by BCS or mastectomy with clear margins of excision. Post-mastectomy positive margins for invasive disease and/or DCIS is not allowed. Multifocal disease (i.e. the presence of two or more foci or breast cancer within the same breast quadrant) and multicentric disease (i.e. the presence of two or more foci of breast cancer in different quadrants of the same breast) are allowed.
- Patients with T3N0 disease are eligible.
- Patients with disease limited to nodal micrometastases are eligible
- Patients with nodal macrometastases (>2mm) treated by axillary dissection must have 1-3 positive axillary nodes (macrometastases, > 2 mm).
Key exclusion criteria (10 listed)
- Patients with nodal disease limited to isolated tumour cells (pN0i+ < 0.2 mm).
- Patients with pT3N1 and pT4 disease (Note: patients with T3N0 are eligible).
- Any prior history, not including the index cancer, of ipsilateral invasive breast cancer or ipsilateral DCIS treated with radiation therapy. (Patients with synchronous or previous ipsilateral LCIS are eligible.)
- Synchronous or previous contralateral invasive breast cancer. (Patients with contralateral DCIS are eligible unless previously treated with radiation.)
- History of non-breast malignancies except adequately treated non-melanoma skin cancers, in situ cancers treated by local excision or other cancers curatively treated with no evidence of disease for ≥ 5 years.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| RadiationRadiotherapy given | Radiation | No Regional Radiotherapy, Regional Radiotherapy |
| No RadiationNo radiotherapy given | Other | No Regional Radiotherapy |
Primary outcome
compare the breast cancer recurrence-free interval (BCRFI) between patients that received regional RT or not
Time frame: 9.5 years
Defined as time from randomization to time of invasive recurrent disease in the ipsilateral chestwall, breast, regional nodes, distant sites or death due to BC.
12 secondary outcomes
Compare the invasive disease-free survival between patients that received regional RT or not.
Time frame: 9.5 years
Compare the breast cancer mortality between patients that received regional RT or not.
Time frame: 9.5 years
Compare the overall survival (OS) between patients that received regional RT or not
Time frame: 9.5 years
Compare the locoregional recurrence-free interval (LRRFI) between patients that received regional RT or not.
Time frame: 9.5 years
Compare the distant recurrence-free interval (DRFI) between patients that received regional RT or not.
Time frame: 9.5 years
Number and severity of adverse events using the current CTCAE version 4
Time frame: 9.5 years
Compare arm volume and mobility measurements between patients that received regional RT or not
Time frame: 9.5 years
Compare patient-reported outcomes (PROs) and the quality of life (QOL) between patients that received regional RT or not
Time frame: 9.5 years
Compare the quality of life (QOL) between patients that received regional RT or not
Time frame: 9.5 years
Compare the cost-effectiveness between patients that received regional RT or not
Time frame: 9.5 years
Compare the quality of life (QOL) between patients that received regional RT or not
Time frame: 9.5 years
Compare the quality of life (QOL) between patients that received regional RT or not
Time frame: 9.5 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Breast Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Timothy Whelan study chair
Juravinski Cancer Centre at Hamilton Health Sciences, Ontario Canada
485 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Radiation and No Radiation in people with Breast Cancer, run by Canadian Cancer Trials Group at 485 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 20 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 1 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 485 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
compare the breast cancer recurrence-free interval (BCRFI) between patients that received regional RT or not (time frame: 9.5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Jul 2026.